首页> 外文OA文献 >Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform
【2h】

Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform

机译:过渡到塞浦路斯的国家卫生系统:利益相关者对药品政策改革的分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective udTo review the pharmaceutical sector in Cyprus in terms of the availability and affordability of medicines and to explore pharmaceutical policy options for the national health system finance reform expected to be introduced in 2016. Methods We conducted semi-structured interviews in April 2014 with senior representatives from seven key national organizations involved in pharmaceutical care. The captured data were coded and analysed using the predetermined themes of pricing, reimbursement, prescribing, dispensing and cost sharing. We also examined secondary data provided by the Cypriot Ministry of Health; these data included the prices and volumes of prescription medicines in 2013 udFindings udWe identified several key issues, including high medicine prices, underuse of generic medicines and high out-of-pocket drug spending. Most stakeholders recommended the national government review existing pricing policies to ensure medicines within the forthcoming national health system are affordable and available, introduce a national reimbursement system and incentivize the prescribing and dispensing of generic medicines. There were disagreements over how to (i) allocate responsibilities to governmental agencies in the national health system, (ii) reconcile differences in opinion between stakeholders and (iii) raise awareness among patients, physicians and pharmacists about the benefits of greater generic drug use. udConclusion udIn Cyprus, if the national health system is going to provide universal health coverage in a sustainable fashion, then the national government must address the current issues in the pharmaceutical sector. Importantly, the country will need to increase the market share of generic medicines to contain drug spending.
机译:目标 ud从药物的可得性和可负担性方面回顾塞浦路斯的制药行业,并探索预期于2016年实施的国家卫生系统财务改革的药物政策选择。方法我们于2014年4月与资深人士进行了半结构化访谈七个参与药物治疗的主要国家组织的代表。使用预定的定价,报销,处方,分配和成本分摊主题对捕获的数据进行编码和分析。我们还检查了塞浦路斯卫生部提供的辅助数据。这些数据包括2013年处方药的价格和数量 udFindings ud我们确定了几个关键问题,包括药品价格高昂,仿制药使用不足和自付费用高。大多数利益相关者建议中央政府审查现有的定价政策,以确保即将到来的国家卫生系统中的药物价格可承受且可用,引入国家报销系统并激励非处方药的处方和配药。关于如何(i)在国家卫生系统中将责任分配给政府机构,(ii)调和利益相关者之间的意见分歧以及(iii)在患者,医生和药剂师之间提高对更大的仿制药使用益处的认识上存在分歧。 ud结论 ud在塞浦路斯,如果国家卫生系统要以可持续的方式提供全民健康覆盖,那么国家政府必须解决制药行业当前的问题。重要的是,该国将需要增加仿制药的市场份额,以控制药物支出。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号